This virtual conference was jointly organised by GARDP and the BSAC. For 2022, we collaborated with the Center For Disease Dynamics, Economics & Policy (CDDEP) and the Indian Council of Medical Research (ICMR).
This conference is RCPath CPD accredited.
Programme
Select to see different time zones. Default is GMT.
SESSION ONE: KEYNOTE PRESENTATION
1030
1130
1600
View session one. This video consists of the following presentations:
1030
1130
1600
Introductory remarks
Professor Laura JV Piddock, Scientific Director, GARDP - View Bio
1035
1135
1605
Regulatory challenges and global access to new antibiotics
Dr Ramanan Laxminarayan, Director, CDDEP - View Bio
SESSION TWO: Early drug discovery: new targets and new chemistry
1115
1215
1645
View session two. This video consists of the following presentations:
1115
1215
1645
Dual fluorescent timer module for screening of anti-persister agents
Professor Ranjana Pathania, Professor Indian Institute of Technology Roorkee (IIT Roorkee) - View Bio
1130
1230
1700
Discovery and optimization of β-sliding clamp (DnaN) inhibitors
Professor Dr Anna Hirsch, Head of department, Drug Design and Optimization (DDOP) Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
1145
1245
1715
New ways to identify novel antibacterial chemical entities - Identification of Novel Antibacterials Using Machine Learning Techniques
Mr Ed Siegwart, Director of Microbiology, Oppilotech Ltd - View Bio
1200
1300
1730
Q&A
SESSION THREE: Preclinical antimicrobial development
1220
1320
1750
View session three. This video consists of the following presentations:
1220
1320
1750
WHO Priority pathogen list and WHO preclinical pipeline analysis
Dr Valeria Gigante, Team Lead, One Health Research Priority-setting and Synergy in AMR, WHO - View Bio
1235
1335
1805
Overview of CARB-X pipeline
Dr Erin Duffy, Chief of Research & Development, CARB-X - View Bio
SESSION FOUR: Panel Discussion
1325
1425
1855
View session four. This video consists of the following presentations:
1325
1425
1855
Evidence for the use of old and new antibiotics
Panellists: Dr Susan Hopkins, Dr Priscilla Rupali, Dr Subasree Srinivasan, Prof. Dr Evelina Tacconelli
Dr Susan Hopkins (UKHSA) - View Bio
Dr Priscilla Rupali (Prof Infectious Diseases, Christian Medical College, Vellore) - View Bio
Dr Subasree Srinivasan (Medical Director, GARDP) - View Bio
Prof. Dr Evelina Tacconelli (University of Verona) - View Bio
1420
1520
1950
Day one closing remarks
Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio
SESSION FIVE: Clinical development
1030
1130
1600
View session five. This video consists of the following presentations:
1030
1130
1600
Introductory remarks
Dr Christopher Longshaw, EU Scientific Advisor, Shionogi & BSAC Honorary Treasurer - View Bio
1035
1135
1605
Overview of clinical pipeline for antimicrobials - will it meet the future unmet need?
Professor Mical Paul, Head, Division of Infectious Diseases, Rambam Health Care Campus, Israel - View Bio
1050
1150
1620
Emerging antibiotic market in the Indian subcontinent
Mr Anmol Aggarwal, Lead, R&D Strategy, Venus Medicine Research Centre, India - View Bio
1105
1205
1635
Clinical development of non-traditional antibiotics
Dr Balganesh Tanjore Soundararajan, President, Gangagen Biotechnologies Pvt Ltd, Bangalore, India - View Bio
1120
1220
1650
Q&A
SESSION SIX: Oral Poster Presentations
1140
1240
1710
View session six. This video consists of the following presentations:
1140
1240
1710
Evaluating the veterinarian role in one health approach at antimicrobial resistance perspectives, Jordan
Bazzi Randa, Faculty of Public Health, University of Debrecen - View Bio
1145
1245
1715
The ESKAPE pathogens mobilome
João Botelho, Postdoctoral Researcher, Max Planck Institute for Evolutionary Biology - View Bio
1150
1250
1720
Utilising health belief model to assess antimicrobial awareness of Western Australian parents: A qualitative study
Aaron Alejandro, PhD Candidate, Murdoch University Australia - View Bio
1155
1255
1725
Nanobodies as inhibitors of the SOS-response: a new class of potential suppressors of antimicrobial resistance
Filippo Vascon, PhD student, Università degli Studi di Padova - View Bio
1200
1300
1730
Phage mediated beta-lactamases and carbapenemases in multi-drug resistant Escherichia coli
Juliet Roshini Mohan Raj, Assistant Professor, Nitte University Centre for Science Education and Research - View Bio
1205
1305
1735
Q&A
SESSION SEVEN: Impact of the COVID-19 pandemic on infections and antimicrobial resistance
1225
1325
1755
View session seven. This video consists of the following presentations:
1225
1325
1755
Impact of Covid 19 on Antimicrobial stewardship
Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine, NHS Greater Glasgow and Clyde - View Bio
1240
1340
1810
How has Indian AMR data changed post-Covid
Dr Kamini Walia, Program officer AMR Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research - View Bio
1255
1355
1825
Impact of Covid-19 on treatment of fungal infections
Dr Arunaloke Chakrabarti, President of International Society for Human and Animal Mycology (ISHAM) - View Bio
1310
1410
1840
Q&A
SESSION EIGHT: Panel Discussion
1330
1430
1900
View session eight. This video consists of the following presentations:
1330
1430
1900
More than one way to do it – R&D of new antimicrobials: incentives and models
Panellists: Dr Anand Anandkumar, Dr Jean-Pierre Paccaud, Ms Jenny Hellmann
Dr Anand Anandkumar, Co-Founder & CEO of Bugworks - View Bio
Dr Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy Global Antibiotic R&D Partnership (GARDP) - View Bio
Ms Jenny Hellmann, Assistant chief of Antibiotics and Infection control unit, Public Health Agency of Sweden - View Bio
1425
1525
1955
Closing remarks
Professor Laura JV Piddock, Scientific Director, GARDP - View Bio
Virtual poster gallery
Click here to view the virtual poster gallery from the conference
